3 completed, 1 active not recruiting, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
Follow Dysgerminoma: new trials by email Literature Review of Dysgerminoma trials Research Report on Dysgerminoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Durvalumab, Tremelimumab - Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2017-05-15 | 2026-09-18 |
| Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment sunitinib malate - Extragonadal Germ Cell Tumor, Ovarian Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 10 | 2007-03-01 | 2015-10-27 |
| Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors pegfilgrastim, cisplatin, ifosfamide - Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 60 | 2007-03-01 | 2017-11-28 |
| Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP) Darbepoetin alfa - Dysgerminoma | Phase 2 | Completed | University Hospital Tuebingen | 108 | 2003-07-01 | 2009-02-16 |
| Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer imatinib mesylate, therapeutic conventional surgery, laboratory biomarker analysis - Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor | Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2002-06-01 | 2013-01-17 |
Seminoma (4) · Testicular Neoplasms (3) · Carcinoma, Embryonal (2) · Endodermal Sinus Tumor (2) · Ovarian Neoplasms (2) · Teratoma (2) · Testicular Germ Cell Tumor (2) · Central Nervous System Neoplasms (1) · Germinoma (1) · Neoplasms, Germ Cell and Embryonal (1) · Nonseminomatous germ cell tumor (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Germinoma (4) · Neoplasms, Germ Cell and Embryonal (4) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Genital Diseases (3) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Gonadal Disorders (3) · Male Urogenital Diseases (3) · Neoplasms by Site (3) · Testicular Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3)
Cisplatin (1) · Darbepoetin alfa (1) · Ifosfamide (1) · Imatinib Mesylate (1) · Paclitaxel (1) · Sunitinib (1) · durvalumab (1) · pegfilgrastim (1) · tremelimumab (1)
Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (1) · University Hospital Tuebingen (1)
United States (4) · Germany (1)
Robert J. Motzer, MD (2) · Christopher Ryan (1) · Darren Feldman, MD (1) · Dean F. Bajorin, MD (1) · Joerg T. Hartmann, MD (1) · Samuel Funt, MD (1)
P30CA008748 (1), U10CA031946 (1)